Skip to Main Content

Paper Details

Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defects.
J Manag Care Spec Pharm
0
2023
Author NameAffiliation
Kim N ChiUniversity of British Columbia
Fred SaadCentre Hospitalier de L'universite de Montreal, Universite de Montreal
Anthony M JoshuaKinghorn Cancer Centre, St. Vincent's Hospital Sydney
  • 1 - 3

Datasets

Release 1.2